Background Correlations among the aqueous flare value (an indicator of inflammation), functional-morphologic parameters, and aqueous humor levels of growth factors/receptors and inflammatory factors/cytokines were investigated in patients with central retinal vein occlusion (CRVO) and macular edema who received intravitreal ranibizumab injection (IRI) and were followed for 6 months. Methods Aqueous humor levels of 11 cytokines or growth inflammatory/factors were measured in 20 CRVO patients with macular edema receiving IRI. Patients with recurrent macular edema were administered further IRI as needed. Aqueous humor levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR), and other cytokines/inflammatory factors were measured by the suspension array method. Aqueous flare values were measured with a laser flare meter and macular edema was examined by optical coherence tomography. Results Compared with before treatment (baseline), the aqueous flare value showed a significant decrease at both 1 month and 6 months after IRI therapy. There were significant correlations between the aqueous flare value and the aqueous levels of sVEGFR-1, placental growth factor, monocyte chemoattractant protein 1, soluble intercellular adhesion molecule-1, interleukin (IL)-6, and IL-8. In addition, a significant correlation was noted between the change of the aqueous flare value and improvement of central macular thickness at 6 months after IRI, as well as a significant correlation between the change of the aqueous flare value and improvement of best-corrected visual acuity at 6 months. Conclusions These findings suggest that IRI reduces inflammation and that the aqueous flare value is influenced by inflammatory factors/cytokines. In addition, the change of the aqueous flare value may be an indicator of the long-term prognosis in CRVO patients receiving IRI therapy for macular edema.

中文翻译：

---

抗血管内皮生长因子剂可减轻视网膜中央静脉阻塞黄斑水肿的炎症。

背景 在接受治疗的视网膜中央静脉阻塞 (CRVO) 和黄斑水肿患者中研究了房水耀斑值（炎症指标）、功能形态学参数和房水生长因子/受体和炎症因子/细胞因子水平之间的相关性。玻璃体内注射雷珠单抗 (IRI) 并随访 6 个月。方法 对 20 例接受 IRI 治疗的黄斑水肿 CRVO 患者的房水 11 种细胞因子或生长炎症/因子水平进行测量。根据需要对复发性黄斑水肿患者进行进一步的 IRI。通过悬浮阵列法测量房水中血管内皮生长因子（VEGF）、可溶性VEGF受体（sVEGFR）和其他细胞因子/炎症因子的水平。用激光耀斑仪测量房水耀斑值，并通过光学相干断层扫描检查黄斑水肿。结果与治疗前（基线）相比，IRI治疗后1个月和6个月房水耀斑值均显着降低。房水耀斑值与房水 sVEGFR-1、胎盘生长因子、单核细胞趋化蛋白 1、可溶性细胞间粘附分子 1、白细胞介素 (IL)-6 和 IL-8 的水平之间存在显着相关性。此外，IRI 后 6 个月房水耀斑值的变化与中央黄斑厚度的改善之间存在显着相关性，房水耀斑值的变化与最佳矫正视力的改善之间存在显着相关性。在 6 个月时。结论 这些发现表明 IRI 可减少炎症，并且房水耀斑值受炎症因子/细胞因子的影响。此外，房水耀斑值的变化可能是 CRVO 患者因黄斑水肿接受 IRI 治疗的长期预后指标。